^
    2d
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12D • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • RET rearrangement • KRAS G12 • KRAS G12S • KRAS Q61
    |
    D3S-002 • elisrasib (D3S-001)
    2d
    Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis. (PubMed, Target Oncol)
    Our study demonstrated that both afatinib and osimertinib as first-line treatments offer favorable median OS in patients with advanced EGFR-mutant NSCLC. In addition, we recommend that patients receiving afatinib as first-line therapy undergo sequential osimertinib treatment, regardless of their T790M mutation status.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    6d
    Engineering Endogenous T Cell Receptors to Recognize Cancer Neoantigens Using a Hybrid Physics-AI Approach. (PubMed, bioRxiv)
    We present an AI-based approach to TCR design with broad utility for efforts to engineer TCRs and for the development of new cell therapies. Artificial intelligence-based approach enables the directed engineering of functional TCRs with enhanced features that target cancer neoantigens.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    6d
    Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study. (PubMed, Int J Cancer)
    Notably, the mean duration of disease progression following EGFR-TKI initiation did not differ significantly between patients with EGFR exon 21 p.L858R mutation and those with EGFR 19-Del. Our study reveals the heterogeneity of compound EGFR mutations, and characterizes the spectrum of acquired resistance mutations to EGFR TKIs.
    Preclinical • Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TYK2 (Tyrosine Kinase 2)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • PIK3CA mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • RAS mutation • EGFR exon 20 mutation
    7d
    Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Ivesa (firmonertinib)
    8d
    Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (clinicaltrials.gov)
    P2, N=156, Completed, European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Aug 2025
    Trial completion • Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M
    |
    Tagrisso (osimertinib) • gefitinib
    8d
    A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=16, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Tepmetko (tepotinib) • Idafang (ivonescimab)
    9d
    Exosomes-Transferred lncRNA H19 Reverses Osimertinib Resistance by Upregulating PTEN via Sponging miR-148-3p in Non-Small Cell Lung Cancer. (PubMed, Oncol Res)
    Exosome-encapsulated lncRNA H19 can be delivered to osimertinib-resistant H1975R cells, thereby reversing resistance through the miR-148-3p/PTEN/PI3K-Akt axis. Our results uncover a potential therapeutic approach to surmount osimertinib resistance in lung cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • H19 (H19 Imprinted Maternally Expressed Transcript)
    |
    EGFR mutation • EGFR T790M
    |
    Tagrisso (osimertinib)
    11d
    Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes. (PubMed, Cancer Sci)
    Among 56 patients who received subsequent systemic therapy, clinical outcomes were comparable between ICI plus platinum doublet and platinum doublet alone. These findings indicate that afatinib and osimertinib provide comparable survival outcomes as first-line therapies for NSCLC with UMs, with treatment effects varying by molecular subtype, while subsequent ICI-based regimens may confer limited additional benefit.
    Journal • Real-world evidence • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib)
    11d
    Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer. (PubMed, Clin Lung Cancer)
    Black patients receiving osimertinib for EGFR-mutated NSCLC had similar outcomes compared to non-black patients.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib)
    12d
    Deciphering the Structural Basis of Allosteric Inhibition of Mutant Epidermal Growth Factor Receptor and Identification of Novel Inhibitors. (PubMed, Comput Struct Biotechnol J)
    This approach identified potential allosteric kinase inhibitors predicted to be more potent than EAI001. Overall, our results elucidate the structural/conformational basis of allosteric inhibition and highlight an MD-integrated approach for targeting dynamic allosteric sites, providing a framework for discovering next-generation modulators that can overcome TKI resistance.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M
    14d
    Detection of Ultralow-Frequency ctDNA Mutations Using a Dual Hairpin-Competition CRISPR/Cas14a System. (PubMed, Anal Chem)
    Compared to ddPCR and next-generation sequencing, DHCC substantially reduces turnaround time and cost while operating on standard qPCR instruments, eliminating the need for specialized infrastructure. By combining ultrahigh sensitivity, PAM independence, multiplexing preamplification capability, and practical affordability, DHCC provides an accessible platform for ctDNA-based liquid biopsy in clinical settings.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • NRAS Q61